Constantine Chinoporos has served as a director of Geron since March 2026. Mr. Chinoporos served as Chief Operating Officer and Chief Business Officer at Applied Therapeutics, Inc., a biopharmaceutical company focused on the treatment of rare metabolic and neuropathic diseases, from December 2023 to February 2026, until the sale of the company to Cycle Pharmaceuticals. Prior to his role at Applied Therapeutics, Mr. Chinoporos served as Chief Business Officer at Albireo Pharmaceuticals, Inc., a rare disease company focused on the treatment of liver diseases, from December 2021 until Albireo's acquisition by Ipsen S.A. in March 2023. Prior to joining Albireo, Mr. Chinoporos served as Chief Business Officer at Boston Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, from November 2015 to October 2021. Prior to that, he held senior positions in worldwide licensing, business development, corporate development, corporate finance and alliance management at Sanofi S.A., Genzyme Corporation, and Eli Lilly and Company. Mr. Chinoporos currently serves as a strategic advisor to Apollo Therapeutics Ltd., a role he has held since February 2023. He served as a member of the Board of Directors and Chair of the Compensation Committee of Elektrofi, Inc., a private drug delivery company acquired by Halozyme Therapeutics, Inc., from December 2019 to November 2025. Mr. Chinoporos holds an M.B.A. from the Johnson Graduate School of Management at Cornell University and a B.A. in History from Cornell University. THE BOARD BELIEVES MR. CHINOPOROS' EXTENSIVE EXPERIENCE IN BIOPHARMACEUTICAL BUSINESS DEVELOPMENT, CORPORATE STRATEGY, AND MAJOR STRATEGIC TRANSACTIONS, HIS EXPERTISE IN SOURCING, STRUCTURING, AND CLOSING LICENSING AND ACQUISITION TRANSACTIONS ACROSS BOTH LARGE PHARMACEUTICAL AND EMERGING BIOTECHNOLOGY ORGANIZATIONS, AS WELL AS HIS KNOWLEDGE OF COMMERCIAL OPERATIONS, ALLIANCE MANAGEMENT, AND HEALTHCARE-RELATED ISSUES, PROVIDES GREAT VALUE TO THE BOARD AND QUALIFIES HIM TO BE ELECTED AS A DIRECTOR.